| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Aselizumab manufacturers
- Aselizumab
-
- $298.00
-
2026-08-19
- CAS:395639-53-9
- Purity: 95.00%
- Supply Ability: 10g
|
| | Aselizumab Basic information |
| Product Name: | Aselizumab | | Synonyms: | Aselizumab;Aselizumab [inn];Bnp 001;Hudreg-55;Immunoglobulin G4, anti-(L-selectin) (human-mouse monoclonal hudreg-55 heavy chain), disulfide with human-mouse monoclonal hudreg-55 light chain, dimer;Research Grade Aselizumab (DHD03301);Research Grade Teneliximab;Research Grade Aselizumab | | CAS: | 395639-53-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Aselizumab Structure]() |
| | Aselizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Aselizumab Usage And Synthesis |
| Uses | Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2]. | | in vivo | Aselizumab (10 mg/kg; i.v.; single dose) shows terminal elimination half-lives at 12.0 days in rhesus monkeys[3].
| | References | [1] Seekamp A, et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial. Crit Care Med. 2004 Oct;32(10):2021-8. DOI:10.1097/01.ccm.0000142396.59236.f3
[2] Rahman I, et al. L-selectin regulates human neutrophil transendothelial migration. J Cell Sci. 2021 Feb 8;134(3):jcs250340. DOI:10.1242/jcs.250340
[3] Co MS, et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology. 1999 Mar;4(3-4):253-66. DOI:10.1016/s1380-2933(98)00024-4 |
| | Aselizumab Preparation Products And Raw materials |
|